Pharmaceutical Preparations · DE · CIK 2023658
Bicara Therapeutics develops bifunctional therapies targeting solid tumors by delivering payloads to tumor sites
Comparable business profile · signals at a glance
In the 90 days to Mar 25, 2026: 1 insider bought $4.8M · 4 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Raben DavidChief Medical Officer | Sell | 5,500 | $18.95 | $104K |
| Mar 23, 2026 | Hyep IvanChief Financial Officer | Sell | 9,200 | $18.52 | $170K |
| Mar 20, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 1,596 | $18.95 | $30K |
| Mar 19, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 6,905 | $18.78 | $130K |
| Mar 18, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 6,499 | $18.84 | $122K |
| Mar 16, 2026 | Cohlhepp RyanPresident and COO | Sell | 8,000 | $19.66 | $157K |
| Mar 16, 2026 | Cohlhepp RyanPresident and COO | Sell | 4,500 | $19.66 | $88K |
| Mar 9, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 36,766 | $19.17 | $705K |
| Mar 6, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 3,817 | $18.75 | $72K |
| Mar 5, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 1,786 | $18.74 | $33K |
| Mar 4, 2026 | Raben DavidChief Medical Officer | Sell | 16,300 | $18.52 | $302K |
| Mar 4, 2026 | Hyep IvanChief Financial Officer | Sell | 2,963 | $18.25 | $54K |
| Mar 4, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 2,631 | $18.73 | $49K |
| Mar 3, 2026 | Hyep IvanChief Financial Officer | Sell | 13,555 | $18.22 | $247K |
| Mar 3, 2026 | Cohlhepp RyanPresident and COO | Sell | 12,892 | $18.16 | $234K |
| Mar 3, 2026 | Cohlhepp RyanPresident and COO | Sell | 4,500 | $18.16 | $82K |
| Mar 3, 2026 | Raben DavidChief Medical Officer | Sell | 200 | $18.45 | $4K |
| Feb 26, 2026 | Ra Capital Management, L.P.Director,TenPercentOwner | Buy | 300,000 | $16.00 | $4.8M |
| Feb 25, 2026 | Cohlhepp RyanPresident and COO | Sell | 3,108 | $18.04 | $56K |
| Feb 25, 2026 | Cohlhepp RyanPresident and COO | Sell | 523 | $18.04 | $9K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.